Breast cancer presents marked molecular and phenotypic heterogeneity, often requires prolonged treatment, and remains prone to drug resistance and recurrence. Conventional chemothe
Diverse molecular and phenotypic variations can be observed across tumour-cell populations, manifested as inter-patient discrepancies, spatial intra-tumour diversity and phenotypic
Breast cancer is a malignant tumor with a high incidence in the world. The treatment of breast cancer is faced with the dual dilemma of unavailability of molecular targets and chem
Breast cancer is a malignant tumor originating from uncontrolled proliferation of breast epithelial cells. The treatment of breast cancer such as chemotherapy, endocrine therapy, t
Currently, antigen receptor T-cells therapy (CAR-T) cell therapy is an innovative immunotherapy that has a high effectiveness in treating certain hematologic cancers. However, desp
Chimeric antigen receptor (CAR)‑T cell therapy has shown significant results in treating blood cancers, but it is not widely used for other reasons: high production costs, long-ter
Breast cancer, which is the most common malignancy in the world for women, has been an enormous burden on human's health. The traditional multimodality therapy, including chemother
Among the most transformative advances in cancer immunotherapy, chimeric antigen receptor (CAR)-T cell therapy and inhibitors of programmed cell death protein 1 (PD-1) stand out, y